PBYI Stock Recent News
PBYI LATEST HEADLINES
Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2024 Earnings Call August 1, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chief Executive Officer, President and Chairman Maximo Nougues - Chief Financial Officer Jeff Ludwig - Chief Commercial Officer Conference Call Participants Marc Frahm - TD Cowen Ed White - H.C. Wainwright Operator Good afternoon.
Puma Biotech (PBYI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to earnings of $0.10 per share a year ago.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its second quarter financial results and hosted a conference call on August 1, 2024.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LOS ANGELES--(BUSINESS WIRE)--On Aug. 1, Puma Biotechnology will issue its earnings results for the 2024 second quarter and follow with a conference call to discuss the results.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology Announced Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer at the 2024 ASCO Annual Meeting.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that findings from the Phase II trial of its drug alisertib (TBCRC 041) were presented at the ASCO 2024 Annual Meeting.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology is on the preliminary list of additions to the Russell 3000 Index.
Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.